John Renger, Chief Scientific Officer at Cerevel Therapeutics Holdings, Inc. (CERE), sold 110,000 shares at $38.59 ($4.4M) on 2021-11-10, disclosed to the SEC on 2021-11-15.
Open-market sale of $4.4M CERE by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.59 | 23,632 | $912K | 20.8% |
| 2 | $38.59 | 23,632 | $912K | 20.8% |
| 3 | $39.61 | 6,135 | $243K | 5.5% |
| 4 | $39.61 | 6,135 | $243K | 5.5% |
| 5 | $40.41 | 10,030 | $405K | 9.2% |
| 6 | $40.41 | 10,030 |
| $405K |
| 9.2% |
| 7 | $41.44 | 13,140 | $545K | 12.4% |
| 8 | $41.44 | 13,140 | $545K | 12.4% |
| 9 | $42.37 | 2,063 | $87K | 2.0% |
| 10 | $42.37 | 2,063 | $87K | 2.0% |
| Total | $39.86 avg | 110,000 | $4.4M | 100% |
| Filing → |
| CERE | SELL | 2022-10-06 | $750K | — | Filing → |
| CERE | SELL | 2022-08-12 | $4.5M | — | Filing → |
| CERE | SELL | 2022-08-09 | $1.0M | — | Filing → |